前列腺癌放疗后的前列腺特异性抗原：对斯坦福大学治疗患者长期生化控制及复发动力学的重新评估
Prostate specific antigen after radiotherapy for prostate cancer: a reevaluation of long-term biochemical control and the kinetics of recurrence in patients treated at Stanford University.
作者信息
Hancock S L, Cox R S, Bagshaw M A
机构信息
Department of Radiation Oncology, Stanford University School of Medicine, California, USA.
出版信息
J Urol. 1995 Oct;154(4):1412-7. doi: 10.1016/s0022-5347(01)66879-4.
PURPOSE
We evaluated prostate specific antigen (PSA) evidence for control of prostatic cancer after irradiation.
MATERIALS AND METHODS
We studied 110 patients for whom more than 2 PSA measurements were obtained to establish trends and the initial measurement was done between April 1985 and January 1988.
RESULTS
A total of 42 patients (38%) had stable, normal PSA levels with followup averaging 12.4 years (range 4.4 to 24.8). Increasing clinical stage or Gleason score correlated significantly with risk for PSA relapse, as did pretreatment PSA level. Short PSA doubling times were associated with distant metastasis rather than with local recurrence.
CONCLUSIONS
We found that irradiation durably controlled 38% of prostatic cancers of various stages and grades and is unlikely to accelerate tumor growth.
目的
我们评估了前列腺特异性抗原（PSA）在放疗后控制前列腺癌方面的证据。
材料与方法
我们研究了110例患者，这些患者进行了超过2次PSA测量以确定趋势，首次测量于1985年4月至1988年1月期间进行。
结果
共有42例患者（38%）PSA水平稳定且正常，随访平均12.4年（范围4.4至24.8年）。临床分期增加或Gleason评分与PSA复发风险显著相关，治疗前PSA水平也是如此。PSA倍增时间短与远处转移相关，而非局部复发。
结论
我们发现放疗能持久控制38%的不同分期和分级的前列腺癌，且不太可能加速肿瘤生长。
Zotero 插件